Local tumour ablative therapies: Opportunities for maximising immune engagement and activation

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 510-523

  O'Brien, Morgan A ^a   Power, Derek G ^b   Clover, A James P ^c   Bird, Brian ^d   Soden, Declan M ^a   Forde, Patrick F ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

^c Department of Medicine National University of Ireland Cork   (Ireland)

^d BON SECOURS HOSPITAL   (Ireland)

Author keywords

DAMPs; Immune blockade; Immune stimulation; Immuno editing; Immunogenic cell death; Tumour ablation

Indexed keywords

ADENOSINE TRIPHOSPHATE; BLEOMYCIN; BORTEZOMIB; CALRETICULIN; CARBOPLATIN; CD134 ANTIGEN; CD40 ANTIGEN; CELL PROTEIN; CP 870893; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DACETUZUMAB; DAMAGE ASSOCIATED MOLECULAR PROTEIN; GEMCITABINE; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; IPILIMUMAB; MITOXANTRONE; NIVOLUMAB; PACLITAXEL; PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; COLORECTAL CANCER; CRYOABLATION; DRUG MECHANISM; ELECTROCHEMOTHERAPY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENIC CELL DEATH; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LEUKEMIA; LYMPHOMA; MELANOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PROSTATE CANCER; PROTEIN SECRETION; RADIOFREQUENCY ABLATION; REVIEW; SMALL CELL LUNG CANCER; SOLID TUMOR; TUMOR ABLATION; TUMOR ESCAPE; TUMOR IMMUNITY; ANIMAL; APOPTOSIS; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; HEAT-SHOCK PROTEINS; HMGB1 PROTEIN; HUMANS; NEOPLASMS; PHOTOCHEMOTHERAPY; TUMOR ESCAPE;

EID: 84908080030     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.09.005     Document Type: Review

References (282)

1. I.A.f.R.o Cancer, GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012, in, Lyon 2013, IARC, France.
2. Medzhitov R., Janeway C.A. Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296:298-300.
3. Janeway C.A., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20:197-216.
4. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. 1998, 95:7556-7561.
5. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
6. Marcen R., Pascual J., Tato A., Teruel J., Villafruela J., Fernandez M., Tenorio M., Burgos F., Ortuno J. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplantation Proceedings 2003, vol. 35:1714-1716. Elsevier.
7. Herman M., Weinstein T., Korzets A., Chagnac A., Ori Y., Zevin D., Malachi T., Gafter U. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J. Lab. Clin. Med. 2001, 137:14-20.
8. Penn I., First M. Development and incidence of cancer following cyclosporine therapy. Transplantation Proceedings 1986, vol. 18:210-215.
9. Frezza E., Fung J., Van Thiel D. Non-lymphoid cancer after liver transplantation. Hepato-Gastroenterology 1996, 44:1172-1181.
10. Dantal J., Hourmant M., Cantarovich D., Giral M., Blancho G., Dreno B., Soulillou J.-P. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998, 351:623-628.
11. Penn I. Cancers following cyclosporins therapy. Transplantation 1987, 43:32-34.
12. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
13. Patel P., Hanson D.L., Sullivan P.S., Novak R.M., Moorman A.C., Tong T.C., Holmberg S.D., Brooks J.T. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann. Intern. Med. 2008, 148:728-736.
14. Shiels M.S., Pfeiffer R.M., Gail M.H., Hall H.I., Li J., Chaturvedi A.K., Bhatia K., Uldrick T.S., Yarchoan R., Goedert J.J. Cancer burden in the HIV-infected population in the United States. J. Natl. Cancer Inst. 2011, 103:753-762.
15. Engels E.A., Brock M.V., Chen J., Hooker C.M., Gillison M., Moore R.D. Elevated incidence of lung cancer among HIV-infected individuals. J. Clin. Oncol. 2006, 24:1383-1388.
16. Coté T.R., Biggar R.J., Rosenberg P.S., Devesa S.S., Percy C., Yellin F.J., Lemp G., Hardy C., Geodert J.J., Blattner W.A. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. Int. J. Cancer 1997, 73:645-650.
17. Maiman M., Fruchter R.G., Clark M., Arrastia C.D., Matthews R., Gates E.J. Cervical cancer as an AIDS-defining illness. Obstet. Gynecol. 1997, 89:76-80.
18. Beral V. Epidemiology of Kaposi's sarcoma. Cancer Surv. 1990, 10:5-22.
19. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
20. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
21. Guerra N., Tan Y.X., Joncker N.T., Choy A., Gallardo F., Xiong N., Knoblaugh S., Cado D., Greenberg N.R., Raulet D.H. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580.
22. Gorgoulis V.G., Vassiliou L.-V.F., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., DiTullio R.A., Kastrinakis N.G., Levy B. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
23. Iannello A., Thompson T.W., Ardolino M., Lowe S.W., Raulet D.H. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J. Exp. Med. 2013, 210:2057-2069.
24. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
25. Smyth M.J., Swann J., Kelly J.M., Cretney E., Yokoyama W.M., Diefenbach A., Sayers T.J., Hayakawa Y. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med. 2004, 200:1325-1335.
26. Tsutsui H., Nakanishi K., Matsui K., Higashino K., Okamura H., Miyazawa Y., Kaneda K. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. 1996, 157:3967-3973.
27. Smyth M.J., Takeda K., Hayakawa Y., Peschon J.J., van den Brink M.R., Yagita H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003, 18:1-6.
28. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors. Immunity 1994, 1:447-456.
29. Bach E.A., Aguet M., Schreiber R.D. The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 1997, 15:563-591.
30. Neumann H., Schmidt H., Cavalie A., Jenne D., Wekerle H. Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-γ and tumor necrosis factor (TNF)-α. J. Exp. Med. 1997, 185:305-316.
31. Gutterman J.U. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. 1994, 91:1198-1205.
32. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., Sasaki S., Imai K., Shibue T., Honda K. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424:516-523.
33. Tough D.F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996, 272:1947-1950.
34. Matikainen S., Sareneva T., Ronni T., Lehtonen A., Koskinen P.J., Julkunen I. Interferon-α activates multiple STAT proteins and upregulates proliferation-associated IL-2Rα, c-myc, and pim-1 genes in human T cells. Blood 1999, 93:1980-1991.
35. Paquette R.L., Hsu N.C., Kiertscher S.M., Park A.N., Tran L., Roth M.D., Glaspy J.A. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 1998, 64:358-367.
36. Radvanyi L., Banerjee A., Weir M., Messner H. Low levels of interferon-alpha induce CD86 (B7. 2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand. J. Immunol. 1999, 50:499-509.
37. Fukunaga A., Miyamoto M., Cho Y., Murakami S., Kawarada Y., Oshikiri T., Kato K., Kurokawa T., Suzuoki M., Nakakubo Y. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004, 28:e26-e31.
38. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18538-18543.
39. Cho Y., Miyamoto M., Kato K., Fukunaga A., Shichinohe T., Kawarada Y., Hida Y., Oshikiri T., Kurokawa T., Suzuoki M. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 2003, 63:1555-1559.
40. Haas W., Pereira P., Tonegawa S. Gamma/delta cells. Annu. Rev. Immunol. 1993, 11:637-685.
41. Boismenu R., Feng L., Xia Y.Y., Chang J., Havran W.L. Chemokine expression by intraepithelial gamma delta T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. J. Immunol. 1996, 157:985-992.
42. Cipriani B., Borsellino G., Poccia F., Placido R., Tramonti D., Bach S., Battistini L., Brosnan C.F. Activation of CC β-chemokines in human peripheral blood γδ T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 2000, 95:39-47.
43. Gao Y., Yang W., Pan M., Scully E., Girardi M., Augenlicht L.H., Craft J., Yin Z. γδ T cells provide an early source of interferon γ in tumor immunity. J. Exp. Med. 2003, 198:433-442.
44. Ma Y., Aymeric L., Locher C., Mattarollo S.R., Delahaye N.F., Pereira P., Boucontet L., Apetoh L., Ghiringhelli F., Casares N. Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 2011, 208:491-503.
45. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 2007, 7:834-846.
46. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
47. Teng M.W., Vesely M.D., Duret H., McLaughlin N., Towne J.E., Schreiber R.D., Smyth M.J. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res. 2012, 72:3987-3996.
48. Wu X., Peng M., Huang B., Zhang H., Wang H., Huang B., Xue Z., Zhang L., Da Y., Yang D. Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Lett. 2013, 340:124-133.
49. Hulpke S., Tampé R. The MHC I loading complex: a multitasking machinery in adaptive immunity. Trends Biochem. Sci. 2013, 38:412-420.
50. Johnsen A., France J., Sy M.-S., Harding C.V. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res. 1998, 58:3660-3667.
51. Yuan J., Liu S., Yu Q., Lin Y., Bi Y., Wang Y., An R. Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma. Acta Histochem. 2013, 115:470-474.
52. Leffers N., Lambeck A.J., de Graeff P., Bijlsma A.Y., Daemen T., van der Zee A.G., Nijman H.W. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecol. Oncol. 2008, 110:365-373.
53. Liu Q., Hao C., Su P., Shi J. Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand. J. Gastroenterol. 2009, 44:960-969.
54. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008, 9:503-510.
55. Li K., Mandai M., Hamanishi J., Matsumura N., Suzuki A., Yagi H., Yamaguchi K., Baba T., Fujii S., Konishi I. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol. Immunother. 2009, 58:641-652.
56. Duan X., Deng L., Chen X., Lu Y., Zhang Q., Zhang K., Hu Y., Zeng J., Sun W. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med. Oncol. 2011, 28:466-474.
57. Kamimura H., Yamagiwa S., Tsuchiya A., Takamura M., Matsuda Y., Ohkoshi S., Inoue M., Wakai T., Shirai Y., Nomoto M. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J. Hepatol. 2012, 56:381-388.
58. Davis M., Conlon K., Bohac G.C., Barcenas J., Leslie W., Watkins L., Lamzabi I., Deng Y., Li Y., Plate J.M. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J. Immunother. 2012, 35:629-640.
59. Villegas F.R., Coca S., Villarrubia V.G., Jiménez R., Chillón M.a.J., Jareño J., Zuil M., Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002, 35:23-28.
60. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Che X., Iwashige H., Aridome K., Hokita S., Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000, 88:577-583.
61. Inman B.A., Frigola X., Dong H., Kwon E.D. Costimulation, coinhibition and cancer. Curr. Cancer Drug Targets 2007, 7:15-30.
62. Gao Q., Wang X.-Y., Qiu S.-J., Yamato I., Sho M., Nakajima Y., Zhou J., Li B.-Z., Shi Y.-H., Xiao Y.-S. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 2009, 15:971-979.
63. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. 2007, 104:3360-3365.
64. Mu C.-Y., Huang J.-A., Chen Y., Chen C., Zhang X.-G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 2011, 28:682-688.
65. Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., Nakamura S., Enomoto K., Yagita H., Azuma M. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 2007, 13:2151-2157.
66. Downey S.G., Klapper J.A., Smith F.O., Yang J.C., Sherry R.M., Royal R.E., Kammula U.S., Hughes M.S., Allen T.E., Levy C.L. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 2007, 13:6681-6688.
67. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25:267.
68. Qin F. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. Cell. Mol. Immunol. 2009, 6:3-13.
69. Shen Z., Zhou S., Wang Y., Li R.-l., Zhong C., Liang C., Sun Y. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J. Cancer Res. Clin. Oncol. 2010, 136:1585-1595.
70. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
71. Hiraoka N., Onozato K., Kosuge T., Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 2006, 12:5423-5434.
72. Kobayashi N., Hiraoka N., Yamagami W., Ojima H., Kanai Y., Kosuge T., Nakajima A., Hirohashi S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 2007, 13:902-911.
73. Yamamoto T., Yanagimoto H., Satoi S., Toyokawa H., Hirooka S., Yamaki S., Yui R., Yamao J., Kim S., Kwon A.-H. Circulating CD4+ CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 2012, 41:409-415.
74. Mole R. Whole body irradiation-radiobiology or medicine?*. Br. J. Radiol. 1953, 26:234-241.
75. Wersäll P.J., Blomgren H., Pisa P., Lax I., Kälkner K.-M., Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006, 45:493-497.
76. Rees G., Ross C. Abscopal Regression Following Radiotherapy for Adenocarcinoma 2014.
77. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., Mu Z., Rasalan T., Adamow M., Ritter E. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 2012, 366:925-931.
78. Blay J.-Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J.-M., Moskovtchenko J.-F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992, 52:3317-3322.
79. Ohba K., Omagari K., Nakamura T., Ikuno N., Saeki S., Matsuo I., Kinoshita H., Masuda J., Hazama H., Sakamoto I. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998, 43:575-577.
80. Macklis R.M., Mauch P.M., Burakoff S.J., Smith B.S. Lymphoid irradiation results in long-term increases in natural killer cells in patients treated for Hodgkin's disease. Cancer 1992, 69:778-783.
81. Uchida A., Mizutani Y., Nagamuta M., Ikenaga M. Effects of X-ray irradiation on natural killer (NK) cell system. L elevation of sensitivity of tumor cells and lytic function of NK cells. Immunopharmacol. Immunotoxicol. 1989, 11:507-519.
82. Sanchez-Ortiz R.F., Tannir N., Ahrar K., Wood C.G. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: in situ tumor vaccine?. J. Urol. 2003, 170:178-179.
83. Camphausen K., Moses M.A., Ménard C., Sproull M., Beecken W.-D., Folkman J., O'Reilly M.S. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003, 63:1990-1993.
84. Kaminski J.M., Shinohara E., Summers J.B., Niermann K.J., Morimoto A., Brousal J. The controversial abscopal effect. Cancer Treat. Rev. 2005, 31:159-172.
85. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
86. Frey B., Rubner Y., Wunderlich R., Weiss E.-M., Pockley A.G., Fietkau R., Gaipl U.S. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation-implications for cancer therapies. Curr. Med. Chem. 2012, 19:1751-1764.
87. Johansson U., Walther-Jallow L., Smed-Sörensen A., Spetz A.-L. Triggering of dendritic cell responses after exposure to activated, but not resting, apoptotic PBMCs. J. Immunol. 2007, 179:1711-1720.
88. Panaretakis T., Kepp O., Brockmeier U., Tesniere A., Bjorklund A.C., Chapman D.C., Durchschlag M., Joza N., Pierron G., van Endert P. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009, 28:578-590.
89. Lauber K., Bohn E., Kröber S.M., Xiao Y.-J., Blumenthal S.G., Lindemann R.K., Marini P., Wiedig C., Zobywalski A., Baksh S. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003, 113:717-730.
90. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
91. Garg A.D., Nowis D., Golab J., Vandenabeele P., Krysko D.V., Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation, Biochimica et Biophysica Acta (BBA)-Reviews on. Cancer 2010, 1805:53-71.
92. Wyllie A. Cell death: a new classification separating apoptosis from necrosis. Cell Death in Biology and Pathology 1981, 9-34. Springer.
93. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.-L., Castedo M., Mignot G., Panaretakis T., Casares N. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
94. Fan T.-J., Han L.-H., Cong R.-S., Liang J. Caspase family proteases and apoptosis. Acta Biochim. Biophys. Sin. 2005, 37:719-727.
95. Zamzami N., Kroemer G. Apoptosis: mitochondrial membrane permeabilization-the (w)hole story?. Curr. Biol. 2003, 13:R71-R73.
96. Michalak M., Corbett E., Mesaeli N., Nakamura K., Opas M. Calreticulin: one protein, one gene, many functions. Biochem. J. 1999, 344:281-292.
97. Gao B., Adhikari R., Howarth M., Nakamura K., Gold M.C., Hill A.B., Knee R., Michalak M., Elliott T. Assembly and antigen-presenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin. Immunity 2002, 16:99-109.
98. Gardai S.J., McPhillips K.A., Frasch S.C., Janssen W.J., Starefeldt A., Murphy-Ullrich J.E., Bratton D.L., Oldenborg P.-A., Michalak M., Henson P.M. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123:321-334.
99. Garg A.D., Krysko D.V., Verfaillie T., Kaczmarek A., Ferreira G.B., Marysael T., Rubio N., Firczuk M., Mathieu C., Roebroek A.J. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012, 31:1062-1079.
100. Tarr J.M., Young P.J., Morse R., Shaw D.J., Haigh R., Petrov P.G., Johnson S.J., Winyard P.G., Eggleton P. A mechanism of release of calreticulin from cells during apoptosis. J. Mol. Biol. 2010, 401:799-812.
101. Obeid M., Panaretakis T., Joza N., Tufi R., Tesniere A., Van Endert P., Zitvogel L., Kroemer G. Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007, 14:1848-1850.
102. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., Aymeric L., Michaud M., Apetoh L., Barault L. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
103. Zitvogel L., Kepp O., Senovilla L., Menger L., Chaput N., Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res. 2010, 16:3100-3104.
104. Obeid M., Panaretakis T., Tesniere A., Joza N., Tufi R., Apetoh L., Ghiringhelli F., Zitvogel L., Kroemer G. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res. 2007, 67:7941-7944.
105. Chen C.-N., Chang C.-C., Su T.-E., Hsu W.-M., Jeng Y.-M., Ho M.-C., Hsieh F.-J., Lee P.-H., Kuo M.-L., Lee H. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann. Surg. Oncol. 2009, 16:524-533.
106. Hsu W.-M., Hsieh F.-J., Jeng Y., Kuo M.-L., Chen C.-N., Lai D.-M., Hsieh L.-J., Wang B.-T., Tsao P.-N., Lee H. Calreticulin expression in neuroblastoma-a novel independent prognostic factor. Ann. Oncol. 2005, 16:314-321.
107. Müller S., Scaffidi P., Degryse B., Bonaldi T., Ronfani L., Agresti A., Beltrame M., Bianchi M.E. The double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 2001, 20:4337-4340.
108. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
109. Bell C.W., Jiang W., Reich C.F., Pisetsky D.S. The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol. 2006, 291:C1318-C1325.
110. Thorburn J., Horita H., Redzic J., Hansen K., Frankel A.E., Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 2008, 16:175-183.
111. Müller S., Ronfani L., Bianchi M. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J. Intern. Med. 2004, 255:332-343.
112. Apetoh L., Ghiringhelli F., Tesniere A., Criollo A., Ortiz C., Lidereau R., Mariette C., Chaput N., Mira J.P., Delaloge S. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 2007, 220:47-59.
113. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
114. van Beijnum J.R., Buurman W.A., Griffioen A.W. Convergence and amplification of Toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008, 11:91-99.
115. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 2009, 28:367-388.
116. Blander J.M., Medzhitov R. Regulation of phagosome maturation by signals from Toll-like receptors. Science 2004, 304:1014-1018.
117. Shiratsuchi A., Watanabe I., Takeuchi O., Akira S., Nakanishi Y. Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J. Immunol. 2004, 172:2039-2047.
118. Tesniere A., Panaretakis T., Kepp O., Apetoh L., Ghiringhelli F., Zitvogel L., Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008, 15:3-12.
119. Tang D., Kang R., Zeh H.J., Lotze M.T. High-mobility group box 1 and cancer. Biochim. Biophys. Acta Gene Regul. Mech. 2010, 1799:131-140.
120. Hendrick J.P., Hartl F. Molecular chaperone functions of heat-shock proteins. Annu. Rev. Biochem. 1993, 62:349-384.
121. Martins I., Kepp O., Schlemmer F., Adjemian S., Tailler M., Shen S., Michaud M., Menger L., Gdoura A., Tajeddine N. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011, 30:1147-1158.
122. Yang W.-L., Nair D.G., Makizumi R., Gallos G., Ye X., Sharma R.R., Ravikumar T. Heat shock protein 70 is induced in mouse human colon tumor xenografts after sublethal radiofrequency ablation. Ann. Surg. Oncol. 2004, 11:399-406.
123. Nikfarjam M., Muralidharan V., Su K., Malcontenti-Wilson C., Christophi C. Patterns of heat shock protein (HSP70) expression and Kupffer cell activity following thermal ablation of liver and colorectal liver metastases. Int. J. Hyperth. 2005, 21:319-332.
124. Wu F., Wang Z.-B., Cao Y.-D., Zhou Q., Zhang Y., Xu Z.-L., Zhu X.-Q. Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation. Ann. Surg. Oncol. 2007, 14:1237-1242.
125. Lanneau D., Brunet M., Frisan E., Solary E., Fontenay M., Garrido C. Heat shock proteins: essential proteins for apoptosis regulation. J. Cell. Mol. Med. 2008, 12:743-761.
126. Wallin R., Lundqvist A., Moré S.H., von Bonin A., Kiessling R., Ljunggren H.-G. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 2002, 23:130-135.
127. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313.
128. Delneste Y., Magistrelli G., Gauchat J.-F., Haeuw J.-F., Aubry J.-P., Nakamura K., Kawakami-Honda N., Goetsch L., Sawamura T., Bonnefoy J.-Y. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002, 17:353-362.
129. Basu S., Binder R.J., Suto R., Anderson K.M., Srivastava P.K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int. Immunol. 2000, 12:1539-1546.
130. Asea A., Rehli M., Kabingu E., Boch J.A., Baré O., Auron P.E., Stevenson M.A., Calderwood S.K. Novel signal transduction pathway utilized by extracellular HSP70 role of Toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. 2002, 277:15028-15034.
131. Zheng H., Dai J., Stoilova D., Li Z. Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J. Immunol. 2001, 167:6731-6735.
132. Singh-Jasuja H., Scherer H.U., Hilf N., Arnold-Schild D., Rammensee H.-G., Toes R.E.M., Schild H. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol. 2000, 30:2211-2215.
133. Doody A.D., Kovalchin J.T., Mihalyo M.A., Hagymasi A.T., Drake C.G., Adler A.J. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J. Immunol. 2004, 172:6087-6092.
134. Binder R.J., Anderson K.M., Basu S., Srivastava P.K. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J. Immunol. 2000, 165:6029-6035.
135. May M.J., Ghosh S. Signal transduction through NF-κB. Immunol. Today 1998, 19:80-88.
136. Feng H., Zeng Y., Graner M.W., Likhacheva A., Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2003, 101:245-252.
137. Dhodapkar M.V., Dhodapkar K.M., Li Z. Role of chaperones and FcγR in immunogenic death. Curr. Opin. Immunol. 2008, 20:512-517.
138. Corriden R., Insel P.A. Basal release of ATP: an autocrine-paracrine mechanism for cell regulation. Sci. Signal. 2010, 3:re1.
139. Lazarowski E.R., Sesma J.I., Seminario-Vidal L., Kreda S.M. Molecular mechanisms of purine and pyrimidine nucleotide release. Adv. Pharmacol. 2011, 61:221.
140. Lazarowski E.R., Boucher R.C., Harden T.K. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol. Pharmacol. 2003, 64:785-795.
141. Martins I., Tesniere A., Kepp O., Michaud M., Schlemmer F., Senovilla L., Séror C., Métivier D., Perfettini J.-L., Zitvogel L. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009, 8:3723-3728.
142. Neumann E., Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J. Membr. Biol. 1972, 10:279-290.
143. 7 receptor-dependent ATP release from B16 melanoma cells. Biochim. Biophys. Acta Gen. Subj. 2010, 1800:40-46.
144. Ferrari D., Sala A.L.A., Chiozzi P., Morelli A., Falzoni S., Girolomoni G., Idzko M., Dichmann S., Norgauer J., Virgilio F.D.I. The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB J. 2000, 14:2466-2476.
145. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
146. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., Shen S., Kepp O., Scoazec M., Mignot G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
147. Aymeric L., Apetoh L., Ghiringhelli F., Tesniere A., Martins I., Kroemer G., Smyth M.J., Zitvogel L. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010, 70:855-858.
148. Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., Formenti S.C. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:862-870.
149. Kalialis L.V., Drzewiecki K.T., Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009, 19:275-282.
150. O'Brien-Ladner A., Nelson M.E., Kimler B.F., Wesselius L.J. Release of interleukin-1 by human alveolar macrophages after in vitro irradiation. Radiat. Res. 1993, 136:37-41.
151. Hong C.-S.C., Tsao C.-Y., Lin P.-Y., WH McBride C.-J., Wu J.-H. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int. J. Radiat. Biol. 1999, 75:1421-1427.
152. Sheard M.A., Vojtesek B., Janakova L., Kovarik J., Zaloudik J. Up-regulation of Fas (CD95) in human p53 wild-type cancer cells treated with ionizing radiation. Int. J. Cancer 1997, 73:757-762.
153. Chakraborty M., Abrams S.I., Coleman C.N., Camphausen K., Schlom J., Hodge J.W. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004, 64:4328-4337.
154. Matsumura S., Wang B., Kawashima N., Braunstein S., Badura M., Cameron T.O., Babb J.S., Schneider R.J., Formenti S.C., Dustin M.L. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 2008, 181:3099-3107.
155. Marks L.B., Friedman H.S., Kurtzberg J., Oakes W.J., Hockenberger B.M. Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor. Med. Pediatr. Oncol. 1992, 20:240-242.
156. Antman K.S., Griffin J.D., Elias A., Socinski M.A., Ryan L., Cannistra S.A., Oette D., Whitley M., Frei E., Schnipper L.E. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N. Engl. J. Med. 1988, 319:593-598.
157. 1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:758-767.
158. Wojciechowska-Lacka A., Matecka-Nowak M., Adamiak E., Lacki J., Cerkaska-Gluszak B. Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma 1995, 43:155-158.
159. Gazelle G.S., Goldberg S.N., Solbiati L., Livraghi T. Tumor ablation with radio-frequency energy 1. Radiology 2000, 217:633-646.
160. Schueller G., Kettenbach J., Sedivy R., Stift A., Friedl J., Gnant M., Lammer J. Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo. Int. J. Oncol. 2004, 24:609-613.
161. Gerdschueller J.K., Sedivy R., Bergmeister H., Stift A., Fried J., Gnant M., Lammer J. Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model. Oncol. Rep. 2004, 12:495-499.
162. Zerbini A., Pilli M., Fagnoni F., Pelosi G., Pizzi M.G., Schivazappa S., Laccabue D., Cavallo C., Schianchi C., Ferrari C. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J. Immunother. 2008, 31:271-282.
163. Zerbini A., Pilli M., Penna A., Pelosi G., Schianchi C., Molinari A., Schivazappa S., Zibera C., Fagnoni F.F., Ferrari C. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006, 66:1139-1146.
164. Zerbini A., Pilli M., Laccabue D., Pelosi G., Molinari A., Negri E., Cerioni S., Fagnoni F., Soliani P., Ferrari C. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 1931-1942, 138(2010):e1932.
165. Gameiro S.R., Higgins J.P., Dreher M.R., Woods D.L., Reddy G., Wood B.J., Guha C., Hodge J.W. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS ONE 2013, 8:e70417.
166. de Baère T., Risse O., Kuoch V., Dromain C., Sengel C., Smayra T., Din M.G.E., Letoublon C., Elias D. Adverse events during radiofrequency treatment of 582 hepatic tumors. Am. J. Roentgenol. 2003, 181:695-700.
167. Jansen M., Van Duijnhoven F., Van Hillegersberg R., Rijken A., Van Coevorden F., Van Der Sijp J., Prevoo W., van Gulik T. Adverse effects of radiofrequency ablation of liver tumours in the Netherlands. Br. J. Surg. 2005, 92:1248-1254.
168. Livraghi T., Lazzaroni S., Meloni F., Solbiati L. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br. J. Surg. 2005, 92:856-858.
169. Llovet J.M., Vilana R., Brú C., Bianchi L.s., Salmeron J.M., Boix L., Ganau S., Sala M., Pagès M., Ayuso C. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001, 33:1124-1129.
170. Gage A.A., Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998, 37:171-186.
171. Hoffmann N.E., Bischof J.C. The cryobiology of cryosurgical injury. Urology 2002, 60:40-49.
172. Yantorno C., Soanes W., Gonder M.J., Shulman S. Studies in cryo-immunology: I. The production of antibodies to urogenital tissue in consequence of freezing treatment. Immunology 1967, 12:395.
173. Shulman S., Brandt E., Yantorno C. Studies in cryo-immunology: II. Tissue and species specificity of the autoantibody response and comparison with isoimmunization. Immunology 1968, 14:149.
174. Gazzaniga S., Bravo A., Goldszmid S.R., Maschi F., Martinelli J., Mordoh J., Wainstok R. Inflammatory changes after cryosurgery-induced necrosis in human melanoma xenografted in nude mice. J. Investig. Dermatol. 2001, 116:664-671.
175. Sabel M.S., Nehs M.A., Su G., Lowler K.P., Ferrara J.L., Chang A.E. Immunologic response to cryoablation of breast cancer. Breast Cancer Res. Treat. 2005, 90:97-104.
176. den Brok M., Sutmuller R.P., Nierkens S., Bennink E.J., Frielink C., Toonen L.W., Boerman O., Figdor C., Ruers T.J., Adema G.J. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br. J. Cancer 2006, 95:896-905.
177. Beyer C., Stearns N.A., Giessl A., Distler J.H., Schett G., Pisetsky D.S. The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death. Innate Immun. 2012, 18:727-737.
178. Bahn D.K., Lee F., Badalament R., Kumar A., Greski J., Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002, 60:3-11.
179. Scale K.K.P. Thoracic masses treated with percutaneous cryotherapy: initial experience with more than 200 procedures. Radiology 2005, 235:289-298.
180. Fucikova J., Kralikova P., Fialova A., Brtnicky T., Rob L., Bartunkova J., Špíšek R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 2011, 71:4821-4833.
181. Panaretakis T., Joza N., Modjtahedi N., Tesniere A., Vitale I., Durchschlag M., Fimia G., Kepp O., Piacentini M., Froehlich K. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008, 15:1499-1509.
182. Schiavoni G., Sistigu A., Valentini M., Mattei F., Sestili P., Spadaro F., Sanchez M., Lorenzi S., D'Urso M.T., Belardelli F. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011, 71:768-778.
183. Bracci L., Moschella F., Sestili P., La Sorsa V., Valentini M., Canini I., Baccarini S., Maccari S., Ramoni C., Belardelli F. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 2007, 13:644-653.
184. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351:1513-1520.
185. Crespi M.D., Ivanier S.E., Genovese J., Baldi A. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem. Biophys. Res. Commun. 1986, 136:521-528.
186. Bellosillo B., Colomer D., Pons G., Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br. J. Haematol. 1998, 100:142-146.
187. Zitvogel L., Kepp O., Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010, 140:798-804.
188. Spisek R., Charalambous A., Mazumder A., Vesole D.H., Jagannath S., Dhodapkar M.V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007, 109:4839-4845.
189. Ling Y.-H., Liebes L., Zou Y., Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J. Biol. Chem. 2003, 278:33714-33723.
190. Verfaillie T., Garg A.D., Agostinis P. Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett. 2013, 332:249-264.
191. Milani M., Rzymski T., Mellor H.R., Pike L., Bottini A., Generali D., Harris A.L. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res. 2009, 69:4415-4423.
192. Mir L.M., Orlowski S., Belehradek J., Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur. J. Cancer Clin. Oncol. 1991, 27:68-72.
193. Mir L.M. Bases and rationale of the electrochemotherapy. Eur. J. Cancer Suppl. 2006, 4:38-44.
194. Serša G., Čemažar M., Miklavčič D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum (II) in mice. Cancer Res. 1995, 55:3450-3455.
195. Petering D.H., Byrnes R.W., Antholine W.E. The role of redox-active metals in the mechanism of action of bleomycin. Chem. Biol. Interact. 1990, 73:133-182.
196. Hecht S.M. Bleomycin: new perspectives on the mechanism of action 1. J. Nat. Prod. 2000, 63:158-168.
197. Bugaut H., Bruchard M., Berger H., Derangère V., Odoul L., Euvrard R., Ladoire S., Chalmin F., Végran F., Rébé C. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS ONE 2013, 8:e65181.
198. Gehl J., Skovsgaard T., Mir L.M. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anti-Cancer Drugs 1998, 9:319-326.
199. Calvet C.Y., Famin D., Andre F.M., Mir L.M. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. OncoImmunology 2014, 3:e28131.
200. Marty M., Sersa G., Garbay J.R., Gehl J., Collins C.G., Snoj M., Billard V., Geertsen P.F., Larkin J.O., Miklavcic D. Electrochemotherapy-an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur. J. Cancer Suppl. 2006, 4:3-13.
201. Garg A.D., Krysko D.V., Vandenabeele P., Agostinis P. The emergence of phox-ER stress induced immunogenic apoptosis. OncoImmunology 2012, 1:786-788.
202. Verfaillie T., Rubio N., Garg A., Bultynck G., Rizzuto R., Decuypere J., Piette J., Linehan C., Gupta S., Samali A. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ. 2012, 19:1880-1891.
203. Garg A.D., Krysko D.V., Vandenabeele P., Agostinis P. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem. Photobiol. Sci. 2011, 10:670-680.
204. Agostinis P., Buytaert E., Breyssens H., Hendrickx N. Regulatory pathways in photodynamic therapy induced apoptosis. Photochem. Photobiol. Sci. 2004, 3:721-729.
205. Garg A.D., Krysko D.V., Vandenabeele P., Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol. Immunother. 2012, 61:215-221.
206. Sanovic R., Verwanger T., Hartl A., Krammer B. Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma. Photodiagn. Photodyn. Ther. 2011, 8:291-296.
207. Kabingu E., Oseroff A.R., Wilding G.E., Gollnick S.O. Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin. Cancer Res. 2009, 15:4460-4466.
208. Castano A.P., Mroz P., Hamblin M.R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 2006, 6:535-545.
209. Hamblin M.R., Castano A.P., Mroz P. Combination immunotherapy and photodynamic therapy for cancer. Biomedical Optics 2006 2006, International Society for Optics and Photonics, (608702-608702-608712).
210. Jenkins M.K., Taylor P.S., Norton S.D., Urdahl K.B. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J. Immunol. 1991, 147:2461-2466.
211. Linsley P.S., Brady W., Grosmaire L., Aruffo A., Damle N.K., Ledbetter J.A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 1991, 173:721-730.
212. L. Immunity 1995, 3:87-98.
213. Krummel M.F., Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 1996, 183:2533-2540.
214. Read S., Malmström V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+ CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med. 2000, 192:295-302.
215. Perez V.L., Van Parijs L., Biuckians A., Zheng X.X., Strom T.B., Abbas A.K. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997, 6:411-417.
216. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995, 182:459-465.
217. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., Thompson C.B., Bluestone J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
218. Kristiansen O., Larsen Z., Pociot F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity?. Genes Immun. 2000, 1.
219. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
220. Reck M., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., Sebastian M., Lu H., Cuillerot J.-M., Lynch T. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 2013, 24:75-83.
221. Hersh E.M., O'Day S.J., Powderly J., Khan K.D., Pavlick A.C., Cranmer L.D., Samlowski W.E., Nichol G.M., Yellin M.J., Weber J.S. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Investig. New Drugs 2011, 29:489-498.
222. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.-F., Testori A., Grob J.-J. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
223. Slovin S., Higano C., Hamid O., Tejwani S., Harzstark A., Alumkal J., Scher H., Chin K., Gagnier P., McHenry M. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann. Oncol. 2013, 24:1813-1821.
224. Slovin S., Beer T., Higano C., Tejwani S., Hamid O., Picus J., Harzstark A., Scher H., Lan Z., Lowy I. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2009, 27:5138.
225. Dewan M.Z., Galloway A.E., Kawashima N., Dewyngaert J.K., Babb J.S., Formenti S.C., Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 2009, 15:5379-5388.
226. Waitz R., Solomon S.B., Petre E.N., Trumble A.E., Fassò M., Norton L., Allison J.P. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012, 72:430-439.
227. Waitz R., Fassò M., Allison J.P. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. OncoImmunology 2012, 1:544-546.
228. Diab A., McArthur H., Solomon S., Comstock C., Maybody M., Sacchini V., Durack J., Gucalp A., Yuan J., Patil S. A pilot study of single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer scheduled for mastectomy. Cancer Res. 2012, 72.
229. Simeone E., Benedetto L., Gentilcore G., Capone M., Caracò C., Di Monta G., Marone U., Di Cecilia M., Grimaldi A.M., Mori S. Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters. J. Transl. Med. 2014, 12:O5.
230. Beck K.E., Blansfield J.A., Tran K.Q., Feldman A.L., Hughes M.S., Royal R.E., Kammula U.S., Topalian S.L., Sherry R.M., Kleiner D. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 2006, 24:2283-2289.
231. Blansfield J.A., Beck K.E., Tran K., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Topalian S.L., Haworth L.R., Levy C. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 1997, 28(2005):593.
232. Sanderson K., Scotland R., Lee P., Liu D., Groshen S., Snively J., Sian S., Nichol G., Davis T., Keler T. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 2005, 23:741-750.
233. Okazaki T., Iwai Y., Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 2002, 14:779-782.
234. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23:515-548.
235. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2:261-268.
236. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
237. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 2008, 8:467-477.
238. Ghebeh H., Mohammed S., Al-Omair A., Qattan A., Lehe C., Al-Qudaihi G., Elkum N., Alshabanah M., Amer S.B., Tulbah A. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors 2006, 8:190.
239. Inman B.A., Sebo T.J., Frigola X., Dong H., Bergstralh E.J., Frank I., Fradet Y., Lacombe L., Kwon E.D. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata. Cancer 2007, 109:1499-1505.
240. Yamazaki T., Akiba H., Iwai H., Matsuda H., Aoki M., Tanno Y., Shin T., Tsuchiya H., Pardoll D.M., Okumura K. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 2002, 169:5538-5545.
241. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., Pennesi G. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 2005, 35:1482-1490.
242. Zhong X., Tumang J.R., Gao W., Bai C., Rothstein T.L. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine binding. Eur. J. Immunol. 2007, 37:2405-2410.
243. Yamazaki T., Akiba H., Koyanagi A., Azuma M., Yagita H., Okumura K. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-γ-induced nitric oxide production. J. Immunol. 2005, 175:1586-1592.
244. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
245. Sznol M., Kluger H.M., Hodi F.S., McDermott D.F., Carvajal R.D., Lawrence D.P., Topalian S.L., Atkins M.B., Powderly J.D., Sharfman W.H. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J. Clin. Oncol. 2013, 31:549s.
246. Zeng J., See A.P., Phallen J., Jackson C.M., Belcaid Z., Ruzevick J., Durham N., Meyer C., Harris T.J., Albesiano E. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86:343-349.
247. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 2005, 23:23-68.
248. Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 2003, 14:265-273.
249. Gramaglia I., Weinberg A.D., Lemon M., Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 1998, 161:6510-6517.
250. Ohshima Y., Tanaka Y., Tozawa H., Takahashi Y., Maliszewski C., Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J. Immunol. 1997, 159:3838-3848.
251. Akiba H., Oshima H., Takeda K., Atsuta M., Nakano H., Nakajima A., Nohara C., Yagita H., Okumura K. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J. Immunol. 1999, 162:7058-7066.
252. Gramaglia I., Jember A., Pippig S.D., Weinberg A.D., Killeen N., Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 2000, 165:3043-3050.
253. Rogers P.R., Song J., Gramaglia I., Killeen N., Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001, 15:445-455.
254. Kjærgaard J., Tanaka J., Kim J.A., Rothchild K., Weinberg A., Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000, 60:5514-5521.
255. Kjaergaard J., Peng L., Cohen P.A., Drazba J.A., Weinberg A.D., Shu S. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 2001, 167:6669-6677.
256. Morris A., Vetto J.T., Ramstad T., Funatake C.J., Choolun E., Entwisle C., Weinberg A.D. Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res. Treat. 2001, 67:71-80.
257. Hirschhorn-Cymerman D., Rizzuto G.A., Merghoub T., Cohen A.D., Avogadri F., Lesokhin A.M., Weinberg A.D., Wolchok J.D., Houghton A.N. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 2009, 206:1103-1116.
258. Gough M.J., Crittenden M.R., Sarff M., Pang P., Seung S.K., Vetto J.T., Hu H.-M., Redmond W.L., Holland J., Weinberg A.D. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control following surgical or radiation therapy of cancer in mice. J. Immunother. 2010, 33:798.
259. Yokouchi H., Yamazaki K., Chamoto K., Kikuchi E., Shinagawa N., Oizumi S., Hommura F., Nishimura T., Nishimura M. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci. 2008, 99:361-367.
260. Alderson M.R., Armitage R.J., Tough T.W., Strockbine L., Fanslow W.C., Spriggs M.K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med. 1993, 178:669-674.
261. Ranheim E.A., Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 1993, 177:925-935.
262. Caux C., Massacrier C., Vanbervliet B., Dubois B., Van Kooten C., Durand I., Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 1994, 180:1263-1272.
263. Mach F., Schönbeck U., Sukhova G.K., Bourcier T., Bonnefoy J.-Y., Pober J.S., Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. 1997, 94:1931-1936.
264. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
265. Yellin M.J., Sinning J., Covey L.R., Sherman W., Lee J.J., Glickman-Nir E., Sippel K.C., Rogers J., Cleary A.M., Parker M. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J. Immunol. 1994, 153:666-674.
266. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: TT help via APC activation. J. Exp. Med. 1996, 184:747-752.
267. Manetti R., Parronchi P., Giudizi M.G., Piccinni M., Maggi E., Trinchieri G., Romagnani S. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 1993, 177:1199-1204.
268. Seder R.A., Gazzinelli R., Sher A., Paul W.E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. 1993, 90:10188-10192.
269. Gazzinelli R.T., Wysocka M., Hieny S., Scharton-Kersten T., Cheever A., Kühn R., Müller W., Trinchieri G., Sher A. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J. Immunol. 1996, 157:798-805.
270. Eliopoulos A.G., Davies C., Knox P.G., Gallagher N.J., Afford S.C., Adams D.H., Young L.S. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol. Cell. Biol. 2000, 20:5503-5515.
271. Funakoshi S., Longo D., Beckwith M., Conley D., Tsarfaty G., Tsarfaty I., Armitage R., Fanslow W., Spriggs M., Murphy W. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994, 83:2787-2794.
272. Hess S., Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med. 1996, 183:159-167.
273. von Leoprechting A., van der Bruggen P., Pahl H.L., Aruffo A., Simon J.C. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 1999, 59:1287-1294.
274. Hirano A., Longo D.L., Taub D.D., Ferris D.K., Young L.S., Eliopoulos A.G., Agathanggelou A., Cullen N., Macartney J., Fanslow W.C. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999, 93:2999-3007.
275. Gladue R., Cole S., Donovan C., Paradis T., Alpert R., Natoli E., Bedian V. In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: impact of tumor CD40 expression, dendritic cells and chemotherapy. J Clin Oncol (Meeting Abstracts) 2006, vol. 24:2514.
276. Bedian V., Donovan C., Garder J. In vitro characterization and pre-clinical pharmacokinetics of CP-870,893, a human anti-CD40 agonist antibody. J. Clin. Oncol. 2006, 24:2539.
277. Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., Sullivan P., Mahany J.J., Gallagher M., Kramer A. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 2007, 25:876-883.
278. Tai Y.-T., Catley L.P., Mitsiades C.S., Burger R., Podar K., Shringpaure R., Hideshima T., Chauhan D., Hamasaki M., Ishitsuka K. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004, 64:2846-2852.
279. Law C.-L., Gordon K.A., Collier J., Klussman K., McEarchern J.A., Cerveny C.G., Mixan B.J., Lee W.P., Lin Z., Valdez P. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005, 65:8331-8338.
280. Advani R., Forero-Torres A., Furman R.R., Rosenblatt J.D., Younes A., Shankles B., Harrop K., Drachman J.G. SGN-40 (anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: evidence of antitumor activity from a phase I study. ASH Annual Meeting Abstracts 2006, vol. 108:695.
281. Honeychurch J., Glennie M.J., Johnson P.W., Illidge T.M. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003, 102:1449-1457.
282. Vonderheide R.H., Burg J.M., Mick R., Trosko J.A., Li D., Shaik M.N., Tolcher A.W., Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. OncoImmunology 2013, 2:e23033.